BiotechTube

Semaglutide + Placebo (semaglutide) + Liraglutide + Placebo (liraglutide)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight

Conditions

Overweight, Obesity

Trial Timeline

Sep 11, 2019 → May 11, 2021

NCT ID
NCT04074161

About Semaglutide + Placebo (semaglutide) + Liraglutide + Placebo (liraglutide)

Semaglutide + Placebo (semaglutide) + Liraglutide + Placebo (liraglutide) is a phase 3 stage product being developed by Novo Nordisk for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT04074161. Target conditions include Overweight, Obesity.

What happened to similar drugs?

0 of 20 similar drugs in Overweight were approved

Approved (0) Terminated (0) Active (20)
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Maridebart cafraglutide + PlaceboAmgenPhase 3
🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3
🔄Semaglutide + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04074161Phase 3Completed

Competing Products

20 competing products in Overweight

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
32
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
29
LY3305677 + PlaceboEli LillyPhase 1
29
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
42
Eloralintide + PlaceboEli LillyPhase 3
47
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
36
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
29
Tirzepatide + AcetaminophenEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
39
Eloralintide + PlaceboEli LillyPhase 3
47
LY3437943 + PlaceboEli LillyPhase 1
29
LY3502970 + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
44
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
LY3541105 + PlaceboEli LillyPhase 1
29
Retatrutide + PlaceboEli LillyPhase 2
35
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
36
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
39